The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.317
Bid: 0.311
Ask: 0.323
Change: 0.0035 (1.12%)
Spread: 0.012 (3.859%)
Open: 0.3135
High: 0.00
Low: 0.00
Prev. Close: 0.3135
IDHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement with Georgia Healthcare Group

17 Dec 2018 09:06

RNS Number : 6528K
Integrated Diagnostics Holdings PLC
17 December 2018
 

Integrated Diagnostics Holdings Plc

Company Announcement

 

17 December 2018

IDH subsidiary Biolab signs agreement with Georgia Healthcare Group to establish a Mega Lab

 

The facility will be the largest of its kind in Georgia and the region with enough capacity to deliver high quality clinical and pathology tests to the country's entire population

 

 

(Cairo and London) - Integrated Diagnostics Holdings ("IDH" or "the Company"), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan and Nigeria, announced today that its Jordan-based subsidiary Biolab has entered into an agreement with Georgia Healthcare Group PLC (GHG) to establish a Mega Laboratory (Mega Lab) in the Georgian capital of Tbilisi.

 

Under the agreement, Biolab will provide GHG with (1) training and management services including the implementation of Biolab's technological platforms and laboratory information management systems (LIMS) and (2) consultancy and support to achieve Joint Commission International Accreditation (JCI) for the Mega Lab within two years from the expected launch date.

 

Biolab will retain up to 10% equity ownership in the Mega Lab and will receive a fixed annual management fee and a share of annualized profits to cover costs and expenses, in addition to an annual service fee.

 

The 7,500 square meter, multi-disciplinary Mega Lab will be the largest of its kind in Georgia and the Caucasus region and will be equipped with state-of-the-art technology covering the full suite of clinical and pathology tests. The Mega Lab will initially serve GHG's network of over 37 hospitals and 16 district polyclinics utilizing one-third of the facility's capacity, with plans to develop a B2B network of healthcare providers outside the Group to reach full utilization.

 

Commenting on the agreement, IDH's Chief Executive Officer Dr. Hend El Sherbini said:

"We are truly excited to be partnering up with Georgia's leading healthcare group and help usher in a new level of service offering to the Georgian population as well as unlock Group-wide operational efficiencies for GHG. IDH's decades-long experience and our position as the operators of the sole JCI-accredited Mega Labs in Egypt and Jordan allow us to provide the necessary know-how, technical training and systems to help this venture succeed. I wish to thank the team at GHG for placing their confidence in us, and I look forward to our Groups' continuous collaboration and support."

-Ends-

About Integrated Diagnostics Holdings

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Scan (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 1,400 diagnostics tests. From its base of 405 branches as of 30 June 2018, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern and African markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015.

 

IDH's forward-looking strategy rests on leveraging its established business model to achieve four key strategic goals, namely: (1) continue to expand customer reach; (2) increase the number of tests per patient; (3) expand into new geographic markets through selective, value-accretive acquisitions; and (4) introduce new medical services by leveraging the Group's network and reputable brand position. Learn more at idhcorp.com.

 

About Georgia Healthcare Group PLC

Georgia Healthcare Group PLC is a UK incorporated holding company of the largest healthcare services provider in the fast-growing, predominantly privately-owned, Georgian healthcare services market. GHG's leadership position is underpinned by offering the most comprehensive range of inpatient and outpatient services targeting the mass market segment through its vertically integrated network of 37 hospitals and 16 district polyclinics. GHG is the single largest market participant, accounting for 25% of total hospital bed capacity in the country, as of 30 September 2018. GHG is also the largest pharmaceuticals retailer and wholesaler in Georgia, with approximately 30% market share by revenue. GHG is the second largest provider of medical insurance in Georgia with a 27% market share based on net insurance premiums earned and approximately 158,000 insurance customers as at September 2018. GHG employed a total of c.15,500 people as at 30 September 2018, including c.3,600 physicians and 2,900 pharmacists.

 

Contact

IDH

+20 (0)2 3345 5530

Sherif El-Ghamrawi, Investor Relations Director

+20 (0)10 0447 8699

sherif.elghamrawi@idhcorp.com

Hudson Sandler (International Media relations)

+44 (0) 207 796 4133

Dan de Belder

Bertie Berger

idh@hudsonsandler.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRTRBLTMBMBMJP
Date   Source Headline
30th Apr 20242:13 pmRNSNotice of AGM
4th Apr 20241:55 pmRNSAnnual Financial Report
28th Mar 20247:00 amRNSFinal Results
26th Mar 20249:15 amRNSNotice of Results
18th Jan 20244:03 pmRNSIDH appoints Group CFO, VP and Board Member
16th Nov 20237:00 amRNS3rd Quarter Results
25th Oct 20237:00 amRNSIDH CEO increases stake in the Company
17th Oct 20231:56 pmRNSDirector/PDMR Shareholding
16th Oct 202312:26 pmRNSDirector/PDMR Shareholding
13th Oct 20232:02 pmRNSDirector/PDMR Shareholding
12th Oct 202310:33 amRNSDirector/PDMR Shareholding
11th Oct 202310:45 amRNSDirector/PDMR Shareholding
31st Aug 20237:00 amRNSHalf-year Report
30th Aug 20239:57 amRNSNotice of Results
21st Jun 202311:18 amRNSCFO & Strategic Investment Officer Appointments
14th Jun 20233:01 pmRNSDirector/PDMR Shareholding
1st Jun 20237:00 amRNS1st Quarter Results
30th May 20235:49 pmRNSResult of AGM
4th May 20233:03 pmRNSAnnual Financial Report & Notice of AGM
28th Apr 20234:01 pmRNSDirector/PDMR Shareholding
18th Apr 20233:23 pmRNSDirector/PDMR Shareholding
6th Apr 202311:05 amRNSFinal Results
6th Apr 20237:00 amRNSPreliminary Results
4th Apr 20236:10 pmRNSNotice of Results
21st Feb 20234:35 pmRNSPrice Monitoring Extension
6th Feb 20234:40 pmRNSSecond Price Monitoring Extn
6th Feb 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSIDH to no longer pursue acquisition of IDC stake
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20227:00 amRNS3rd Quarter Results
10th Nov 20221:55 pmRNSNotice of Results
31st Oct 202210:06 amRNSIDH launches Greenfield in KSA with Izhoor
5th Oct 20221:09 pmRNSIDH launches sixth Al-Borg Scan Branch
5th Oct 202212:49 pmRNSAl-Borg Scan obtains ACR Accreditation
12th Sep 20228:23 amRNSHalf-year Report
7th Sep 20224:04 pmRNSNotice of Results
6th Sep 20229:30 amRNSIDC termination; negotiations ongoing
22nd Aug 20224:40 pmRNSSecond Price Monitoring Extn
22nd Aug 20224:36 pmRNSPrice Monitoring Extension
17th Aug 20224:41 pmRNSSecond Price Monitoring Extn
17th Aug 20224:36 pmRNSPrice Monitoring Extension
16th Aug 20222:09 pmRNSIDH CEO ups stake in the Company
16th Aug 202211:19 amRNSDirector/PDMR Shareholding
15th Aug 20224:41 pmRNSSecond Price Monitoring Extn
15th Aug 20224:36 pmRNSPrice Monitoring Extension
11th Aug 20226:01 pmRNSDirector/PDMR Shareholding
11th Aug 20225:44 pmRNSDirector/PDMR Shareholding
9th Aug 20225:27 pmRNSDirector/PDMR Shareholding
9th Aug 20222:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.